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Abstract
While there are existing databases that curate only drug, target, or pathway data for instance, 
none of these alone are exhaustive. The Drug Gene Pathway (DRUGPATH) meta database 
was created as a response to the complex treatment required for various diseases including 
Gulf War Illness (GWI) and post-traumatic stress disorder (PTSD), where therapy involves 
using multiple drugs in combination. Here, drug-drug interactions can occur due to the 
promiscuous nature of pharmaceuticals, which can then lead to various side effects or can 
alternatively be utilized towards drug repurposing. The objective was to develop a database that 
maps the interactions between drugs, genes, pathways, and targets for use in the treatment of 
complex diseases, including the prediction of off-target interactions, otherwise known as side 
effects. Using MATLAB and Python scripts, interactions between known drugs, genes, targets, 
and pathways amalgamated from numerous expert-curated sources such as PharmGKB, 
DrugBank, DGIdb, ConsesusPathDB, Guide to PHARMACOLOGY, HUGO Gene Nomenclature 
Committee, Toxin and Toxin-Target Database, repoDB, the FDA’s National Drug Code 
database, etc. were mapped together. The raw data was first downloaded from its source and 
subsequently cleaned, where extraneous information such as data from non-humans, internal 
identifiers, timestamps, etc. were removed. The remaining information was then integrated into 
an SQLite database. DRUGPATH currently contains a total of 2,632,516 unique entries, and of 
these, there are 54,757 unique genes, 2,632,242 unique pathways, and 31,042 unique drugs. 
DRUGPATH allows researchers and clinicians to discern which pathways are affected by each 
drug, reducing the likelihood of an adverse drug reaction occurring. The incorporation of drug, 
gene, target, and pathway information makes DRUGPATH a powerful resource for predicting 
potential side effects when designing or refining a given drug combination therapy. Not only 
that, but we have additionally added the FDA status, half-life, and indication for each drug 
whenever possible for clinical applications of this database.
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